|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 225.46 USD | -0.28% |
|
+0.18% | +26.90% |
| 06:39pm | OSE Immunotherapeutics Amends Partnership With AbbVie for Inflammation Drug Development | MT |
| 06:19pm | OSE Immunotherapeutics Amends Partnership Agreement with AbbVie on ABBV-230 |  |
| Capitalization | 400B 344B 323B 300B 553B 36,022B 604B 3,763B 1,457B 17,008B 1,500B 1,468B 62,311B | P/E ratio 2025 * |
52.8x | P/E ratio 2026 * | 23.2x |
|---|---|---|---|---|---|
| Enterprise value | 456B 392B 368B 342B 631B 41,073B 688B 4,290B 1,661B 19,392B 1,710B 1,673B 71,047B | EV / Sales 2025 * |
7.48x | EV / Sales 2026 * | 6.7x |
| Free-Float |
96.39% | Yield 2025 * |
2.89% | Yield 2026 * | 3% |
Last Transcript: AbbVie Inc.
| 1 day | -0.29% | ||
| 1 week | +0.18% | ||
| Current month | -0.96% | ||
| 1 month | +3.11% | ||
| 3 months | +7.49% | ||
| 6 months | +19.22% | ||
| Current year | +26.90% |
| 1 week | 223.11 |  | 230.94 |
| 1 month | 216.15 | | 239.29 |
| Current year | 164.39 | | 244.81 |
| 1 year | 164.39 | | 244.81 |
| 3 years | 130.96 | | 244.81 |
| 5 years | 101.55 | | 244.81 |
| 10 years | 50.71 | | 244.81 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Michael
CEO | Chief Executive Officer | 54 | 01/07/2024 |
Scott Reents
DFI | Director of Finance/CFO | 58 | 23/06/2022 |
Roopal Thakkar
CTO | Chief Tech/Sci/R&D Officer | - | 01/01/2003 |
| Director | Title | Age | Since |
|---|---|---|---|
Roxanne Austin
BRD | Director/Board Member | 64 | 01/01/2013 |
William Burnside
BRD | Director/Board Member | 73 | 01/01/2013 |
Edward Rapp
BRD | Director/Board Member | 67 | 01/01/2013 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 7.12% | 6 M€ | 0.00% | - |
| 6.85% | 26 M€ | +11.85% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.28% | +0.18% | +27.72% | +35.86% | 400B | |
| -1.46% | -5.94% | +23.82% | +167.63% | 905B | |
| +0.23% | -1.18% | +35.64% | +14.51% | 487B | |
| +2.19% | +2.82% | +23.52% | +4.87% | 330B | |
| -0.10% | -1.86% | +26.87% | +19.99% | 281B | |
| -0.41% | +2.28% | +19.31% | +25.02% | 255B | |
| -0.37% | -2.39% | -4.23% | -10.33% | 248B | |
| -3.42% | -4.91% | -61.78% | -33.36% | 214B | |
| -1.74% | -3.82% | +16.91% | +13.66% | 178B | |
| +0.36% | -2.02% | +34.48% | +36.16% | 150B | |
| Average | -0.52% | -2.37% | +14.23% | +27.40% | 344.69B | |
| Weighted average by Cap. | -0.54% | -2.83% | +18.60% | +53.61% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 60.93B 52.45B 49.24B 45.77B 84.36B 5,493B 92.04B 574B 222B 2,593B 229B 224B 9,501B | 66.62B 57.35B 53.83B 50.04B 92.24B 6,006B 101B 627B 243B 2,836B 250B 245B 10,389B |
| Net income | 9.1B 7.83B 7.35B 6.83B 12.6B 820B 13.74B 85.68B 33.18B 387B 34.15B 33.42B 1,419B | 17.43B 15B 14.08B 13.09B 24.13B 1,571B 26.33B 164B 63.55B 742B 65.41B 64.01B 2,718B |
| Net Debt | 56.02B 48.22B 45.27B 42.08B 77.57B 5,050B 84.63B 528B 204B 2,385B 210B 206B 8,736B | 46.47B 40B 37.55B 34.91B 64.35B 4,189B 70.2B 438B 169B 1,978B 174B 171B 7,247B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/12/25 | 225.38 $ | -0.31% | 996,749 |
| 05/12/25 | 226.08 $ | -1.15% | 3,985,199 |
| 04/12/25 | 228.71 $ | -0.66% | 3,733,100 |
| 03/12/25 | 230.24 $ | +2.62% | 4,873,263 |
| 02/12/25 | 224.37 $ | -0.33% | 5,096,922 |
Delayed Quote Nyse, 09 December 2025 at 04:05 am AEDT
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ABBV Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition